Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
33
TRML Quote, Financials, Valuation and Earnings
Last price:
$47.98
Seasonality move
:
28.01%
Day range:
$47.98 - $47.98
52-week range:
$11.56 - $48.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.76x
Volume:
--
Avg. volume:
47.1K
1-year change:
99.67%
Market cap:
$1.2B
Revenue:
--
EPS (TTM):
-$3.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRML
Tourmaline Bio, Inc.
|
-- | -$0.98 | -- | -9.63% | $48.00 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.21% | 32.99% | $130.63 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 30.99% | 53.99% | $1,056.70 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.81% | 38.62% | $106.62 |
|
NVS
Novartis AG
|
$13.9B | $2.31 | 4.45% | 37.94% | $134.88 |
|
UNH
UnitedHealth Group, Inc.
|
$113.6B | $6.58 | 12.53% | -65.23% | $388.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRML
Tourmaline Bio, Inc.
|
$47.98 | $48.00 | $1.2B | -- | $0.00 | 0% | -- |
|
GILD
Gilead Sciences, Inc.
|
$121.22 | $130.63 | $150.4B | 18.78x | $0.79 | 2.59% | 5.24x |
|
LLY
Eli Lilly & Co.
|
$1,010.31 | $1,056.70 | $904.2B | 49.97x | $1.50 | 0.59% | 15.50x |
|
MRK
Merck & Co., Inc.
|
$99.72 | $106.62 | $247.5B | 13.19x | $0.81 | 3.25% | 3.93x |
|
NVS
Novartis AG
|
$132.16 | $134.88 | $253.6B | 18.02x | $3.99 | 3.02% | 4.78x |
|
UNH
UnitedHealth Group, Inc.
|
$330.91 | $388.52 | $299.8B | 17.27x | $2.21 | 2.61% | 0.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRML
Tourmaline Bio, Inc.
|
0.06% | 1.823 | 0.04% | 23.70x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
NVS
Novartis AG
|
41.94% | 0.086 | 12.99% | 0.58x |
|
UNH
UnitedHealth Group, Inc.
|
45.55% | -0.149 | 24.83% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRML
Tourmaline Bio, Inc.
|
-$12K | -$26M | -29.5% | -29.52% | -- | -$20.3M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
UNH
UnitedHealth Group, Inc.
|
-- | $4.3B | 9.95% | 17.57% | 2.85% | $5.1B |
Tourmaline Bio, Inc. vs. Competitors
-
Which has Higher Returns TRML or GILD?
Gilead Sciences, Inc. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 39.21%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital TRMLTourmaline Bio, Inc.-- -$0.90 $259.3M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About TRML or GILD?
Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 7.77%. Given that Gilead Sciences, Inc. has higher upside potential than Tourmaline Bio, Inc., analysts believe Gilead Sciences, Inc. is more attractive than Tourmaline Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRMLTourmaline Bio, Inc.1 6 0 GILDGilead Sciences, Inc.16 8 0 -
Is TRML or GILD More Risky?
Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock TRML or GILD?
Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.59% to investors and pays a quarterly dividend of $0.79 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios TRML or GILD?
Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 5.24x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRMLTourmaline Bio, Inc.-- -- -- -$23.1M GILDGilead Sciences, Inc.5.24x 18.78x $7.8B $3.1B
-
Which has Higher Returns TRML or LLY?
Eli Lilly & Co. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 31.72%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital TRMLTourmaline Bio, Inc.-- -$0.90 $259.3M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About TRML or LLY?
Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.59%. Given that Eli Lilly & Co. has higher upside potential than Tourmaline Bio, Inc., analysts believe Eli Lilly & Co. is more attractive than Tourmaline Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRMLTourmaline Bio, Inc.1 6 0 LLYEli Lilly & Co.17 8 0 -
Is TRML or LLY More Risky?
Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock TRML or LLY?
Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TRML or LLY?
Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 49.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 15.50x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRMLTourmaline Bio, Inc.-- -- -- -$23.1M LLYEli Lilly & Co.15.50x 49.97x $17.6B $5.6B
-
Which has Higher Returns TRML or MRK?
Merck & Co., Inc. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 33.68%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital TRMLTourmaline Bio, Inc.-- -$0.90 $259.3M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About TRML or MRK?
Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Merck & Co., Inc. has higher upside potential than Tourmaline Bio, Inc., analysts believe Merck & Co., Inc. is more attractive than Tourmaline Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRMLTourmaline Bio, Inc.1 6 0 MRKMerck & Co., Inc.14 13 0 -
Is TRML or MRK More Risky?
Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock TRML or MRK?
Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TRML or MRK?
Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRMLTourmaline Bio, Inc.-- -- -- -$23.1M MRKMerck & Co., Inc.3.93x 13.19x $17.2B $5.8B
-
Which has Higher Returns TRML or NVS?
Novartis AG has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 28.26%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital TRMLTourmaline Bio, Inc.-- -$0.90 $259.3M NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About TRML or NVS?
Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 2.06%. Given that Novartis AG has higher upside potential than Tourmaline Bio, Inc., analysts believe Novartis AG is more attractive than Tourmaline Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRMLTourmaline Bio, Inc.1 6 0 NVSNovartis AG1 6 2 -
Is TRML or NVS More Risky?
Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.
-
Which is a Better Dividend Stock TRML or NVS?
Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.02% to investors and pays a quarterly dividend of $3.99 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TRML or NVS?
Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.9B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than Novartis AG's net income of $3.9B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 4.78x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRMLTourmaline Bio, Inc.-- -- -- -$23.1M NVSNovartis AG4.78x 18.02x $13.9B $3.9B
-
Which has Higher Returns TRML or UNH?
UnitedHealth Group, Inc. has a net margin of -- compared to Tourmaline Bio, Inc.'s net margin of 2.25%. Tourmaline Bio, Inc.'s return on equity of -29.52% beat UnitedHealth Group, Inc.'s return on equity of 17.57%.
Company Gross Margin Earnings Per Share Invested Capital TRMLTourmaline Bio, Inc.-- -$0.90 $259.3M UNHUnitedHealth Group, Inc.-- $2.59 $185.9B -
What do Analysts Say About TRML or UNH?
Tourmaline Bio, Inc. has a consensus price target of $48.00, signalling upside risk potential of 0.04%. On the other hand UnitedHealth Group, Inc. has an analysts' consensus of $388.52 which suggests that it could grow by 17.41%. Given that UnitedHealth Group, Inc. has higher upside potential than Tourmaline Bio, Inc., analysts believe UnitedHealth Group, Inc. is more attractive than Tourmaline Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRMLTourmaline Bio, Inc.1 6 0 UNHUnitedHealth Group, Inc.12 6 2 -
Is TRML or UNH More Risky?
Tourmaline Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UnitedHealth Group, Inc. has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.182%.
-
Which is a Better Dividend Stock TRML or UNH?
Tourmaline Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group, Inc. offers a yield of 2.61% to investors and pays a quarterly dividend of $2.21 per share. Tourmaline Bio, Inc. pays -- of its earnings as a dividend. UnitedHealth Group, Inc. pays out 52.75% of its earnings as a dividend. UnitedHealth Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TRML or UNH?
Tourmaline Bio, Inc. quarterly revenues are --, which are smaller than UnitedHealth Group, Inc. quarterly revenues of $113.2B. Tourmaline Bio, Inc.'s net income of -$23.1M is lower than UnitedHealth Group, Inc.'s net income of $2.5B. Notably, Tourmaline Bio, Inc.'s price-to-earnings ratio is -- while UnitedHealth Group, Inc.'s PE ratio is 17.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio, Inc. is -- versus 0.70x for UnitedHealth Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRMLTourmaline Bio, Inc.-- -- -- -$23.1M UNHUnitedHealth Group, Inc.0.70x 17.27x $113.2B $2.5B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.94% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.12% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.82% over the past day.
